Anti Infectives Volume 2 (Frontiers in Clinical Drug Research - Anti Infectives)
Description:
Frontiers in Clinical Drug Research - Anti infectives is an eBook series that brings updated reviews to readers interested in learning about advances in the development of pharmaceutical agents for the treatment of infectious diseases. The scope of the eBook series covers a range of topics including the chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs employed in the treatment of infectious diseases. Reviews in this series also include research on multi drug resistance and pre-clinical / clinical findings on novel antibiotics, vaccines, antifungal agents and antitubercular agents. Frontiers in Clinical Drug Research - Anti infectives is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of anti infective drug discovery and epidemiology.The second: Volume of this series features reviews that cover a variety of topics including: -Identification of nosocomial pathogens and antimicrobials using phenotypic techniques-Topical antimicrobials-Anti-infective drug safety-Antimicrobial resistance... and much more.
Best prices to buy, sell, or rent ISBN 9781681081540
Frequently Asked Questions about Anti Infectives Volume 2 (Frontiers in Clinical Drug Research - Anti Infectives)
The price for the book starts from $108.26 on Amazon and is available from 1 sellers at the moment.
If you’re interested in selling back the Anti Infectives Volume 2 (Frontiers in Clinical Drug Research - Anti Infectives) book, you can always look up BookScouter for the best deal. BookScouter checks 30+ buyback vendors with a single search and gives you actual information on buyback pricing instantly.
As for the Anti Infectives Volume 2 (Frontiers in Clinical Drug Research - Anti Infectives) book, the best buyback offer comes from and is $ for the book in good condition.
Not enough insights yet.
Not enough insights yet.